CASTLE BIOSCIENCES INC

Castle Biosciences insider trades reveal a disciplined liquidity strategy, not a red flag. Understand how senior sales align with strong oncology diagnostics growth and investor outlook.

Castle Biosciences insider sale: CEO’s 1,730 shares sold under Rule 10b5‑1 amid a 60% YTD price jump and earnings beat—insightful look at liquidity, strategy, and investor signals.

Castle Biosciences CFO sale reveals a liquidity‑buffer strategy, not panic – insiders stay invested while dual‑listing boosts liquidity and long‑term prospects.